drugset / Trial / NCT01768247
HCG (Human Chorionic Gonadotropin) Priming for Thin Endometrium in IVF (in Vitro Fertilization)
Phase 4
Unknown
15 enrolled
University Hospital Brussels
Human Reproduction & Genetics Foundation · collab
NaSingle-groupOpen-labelTreatment
Summary
A thin endometrium is one of the most difficult problems encountered in assisted reproduction every day practice Regarding the proliferative phase, several ways of treatment have been undertaken to circumvent thin endometrium trying to increase thickness with questionable results. The objective of the current study will be whether a daily dose of 150 IU (international units) of human chorionic gonadotropin (HCG) for seven days concomitant with estrogen administration in estrogen replacement cycles can increase the endometrial thickness and improve pregnancy outcome.
Timeline
- Start
- 2012-01
- Primary completion
- 2013-12
- Completion
- 2014-01
Publications
- Background Shufaro Y, Simon A, Laufer N, Fatum M. Thin unresponsive endometrium--a possible complication of surgical curettage compromising ART outcome. J Assist Reprod Genet. 2008 Aug;25(8):421-5. doi: 10.1007/s10815-008-9245-y. Epub 2008 Sep 17.
- Papanikolaou EG, Kyrou D, Zervakakou G, Paggou E, Humaidan P. "Follicular HCG endometrium priming for IVF patients experiencing resisting thin endometrium. A proof of concept study". J Assist Reprod Genet. 2013 Oct;30(10):1341-5. doi: 10.1007/s10815-013-0076-0. Epub 2013 Aug 16.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | human chorionic gonadotropin | Protein / enzyme biologic | 150 iu | Subcutaneous |
Indications
No indication recorded.